Seminars in Oncology
Volume 33, Issue 6 , Pages 650-656 , December 2006

Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer

  • Cynthia X. Ma
    • ,
  • Matthew J. Ellis

      Affiliations

    • Corresponding Author InformationAddress correspondence to Matthew J. Ellis, MB, PhD, FRCP, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110.

References 

  1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717
  2. Baum M, Demicheli R, Hrushesky W, et al. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases?. Eur J Cancer. 2005;41:508–515
  3. Akhtar SS, Allan SG, Rodger A, et al. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol. 1991;17:30–35
  4. Bradbeer JW, Kyngdon J. Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol. 1983;9:31–34
  5. Horobin JM, Preece PE, Dewar JA, et al. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78:213–217
  6. Fentiman IS, Christiaens MR, Paridaens R, et al. Treatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39:309–316
  7. Kenny FS, Robertson JFR, Ellis IO, et al. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast. 1998;7:335–339
  8. Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994;20:207–214
  9. Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699–704
  10. Bates T, Riley DL, Houghton J, et al. The Elderly Breast Cancer Working Party Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg. 1991;78:591–594
  11. Mustacchi G, Milani S, Pluchinotta A, et al. Group for Research on Endocrine Therapy in the Elderly Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Anticancer Res. 1994;14:2197–2200
  12. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14:414–420
  13. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–1532
  14. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–5116
  15. Abrial C, Mouret-Reynier MA, Cure H, et al. Neoadjuvant endocrine therapy in breast cancer. Breast. 2006;15:9–19
  16. Cataliotti L, Buzdar A, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women in hormone-receptor positive breast cancer. Cancer. 2006;106:2095–2103
  17. Semiglazov V, Semiglazov VV, Ivanov VG, et al. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1-4N1-2M0). Breast Cancer Res Treat. 2003;82:S22;(suppl 1, abstr 111)
  18. Paik S, Shak S, Tang G, et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat. 2004;88:S16;(suppl 1, abstr 24)
  19. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  20. Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91:2012–2017
  21. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539–1545
  22. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm (Results of a randomized trial in a single centre). Ann Oncol. 1991;2:347–354
  23. Semiglazov VF, Semiglazov VV, Ivanov V, et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. J Clin Oncol ASCO Proceedings (Post-Meeting Edition). 2004;22:519;(abstr)
  24. Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: More questions than answers. J Clin Oncol. 2005;23:4842–4844
  25. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  26. Viale G, Regan M, Dell’Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat. 2005;94:S13;(suppl 1, abstr 44)
  27. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—A study from the IMPACT trialists. J Clin Oncol. 2005;23:2477–2492
  28. Miller WR, Anderson TJ, White S, et al. Aromatase inhibitors: Cellular and molecular effects. J Steroid Biochem Mol Biol. 2005;95:83–89
  29. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006;24:3019–3025
  30. Miller WR, Anderson TJ, Hawkins RA, et al. Neoadjuvant endocrine treatment: the Edinburgh experience. In:  Howell A,  Dowsett M editor. Primary Medical Therapy for Breast Cancer ESO Scientific Updates. Amsterdam: Elsevier; 1999;p. 1–11
  31. Miller WR, Krause A, Evans DB, et al. Phenotypes for endocrine resistance can be identified by RNA microarray of sequential biopsies and are more variable than those predicting for tumour response. Breast Cancer Res Treat. 2005;94:S17;(suppl 1, abstr 31)
  32. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–3816
  33. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168
  34. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874
  35. Wong ZW, Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: An over looked option?. Oncology (Williston Park). 2004;18:411–420

PII: S0093-7754(06)00324-1

doi: 10.1053/j.seminoncol.2006.08.013

Seminars in Oncology
Volume 33, Issue 6 , Pages 650-656 , December 2006

Article Tools

* Image Usage & Resolution